Case Study
Boehringer Ingelheim
Having GPP is a Tough Job
- SectorHealth & Wellness
- OfficeCanada
General Pustular Psoriasis (GPP) is a rare and debilitating skin disease that may be life-threatening. Currently in Canada there are no approved prescription medications or treatment guidelines specifically for GPP.
Boehringer Ingelheim Canada (BI) developed Spesolimab, a prescription treatment for GPP that is currently being reviewed by Health Canada under its Priority Review Policy. In advance of Health Canada’s approval and availability in Canada, BI’s goal was to raise awareness of GPP. We created an integrated, digital-first campaign that told Kate’s story navigating like with GPP. Key results included: 2.8 million impressions, 898,595 video views, 741,122 engagements and a total reach of 1.1 million.